Prime Medicine ($PRME) Stock Forecast: Down 10.8% Today

What is Prime Medicine?

PRME (Prime Medicine) is a biotechnology company listed on NASDAQ. Today, the stock experienced a significant bearish movement.

Why is Prime Medicine going down?

PRME stock is down 10.8% on Oct 2, 2024 13:45

• PRME stock rose by 11.8% due to a collaboration announcement with Bristol Myers Squibb for the development of T-cell therapies.
• Despite positive developments, PRME faced a bearish trend, possibly due to profit-taking by investors after a recent sharp rise in stock price.
• The overall market sentiment was slightly lower with the Dow Jones index falling around 0.1%, which might have contributed to the downward pressure on PRME stock.
• Investors might be cautious about the timeline for the initial clinical data from Phase 1/2 trials in CGD expected in 2025, leading to some selling pressure on the stock.

PRME Price Chart

PRME Technical Analysis

PRME News

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.

https://www.zacks.com/stock/news/2344359/prme-stock-rises-118-on-collaboration-with-bristol-myers

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday - Prime Medicine ( NASDAQ:PRME )

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Prime Medicine, Inc. PRME rose sharply during Monday's session after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for ...

https://www.benzinga.com/news/24/09/41096426/prime-medicine-miniso-group-li-auto-weibo-and-other-big-stocks-moving-higher-on-monday

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Bristol-Myers Squibb ( NYSE:BMY ) , Prime Medicine ( NASDAQ:PRME )

On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.

https://www.benzinga.com/general/biotech/24/09/41091774/prime-medicine-inks-cell-therapy-pact-with-bristol-myers-squibb-worth-over-3-5b-streamlines-pipel

Prime Medicine Unveils Strategically Focused Pipeline

-- Prioritizing Set of High Value Programs in Core Areas of Focus. Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's ...

https://www.globenewswire.com/news-release/2024/09/30/2955070/0/en/Prime-Medicine-Unveils-Strategically-Focused-Pipeline.html

Trending Today

Cardano ($ADA) Crypto Forecast: Up 19.2% Today

XRP ($XRP) Crypto Forecast: Up 17.6% Today

Applovin Corporation ($APP) Stock Forecast: Up 5.1% Today

The Boeing Company ($BA) Stock Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 6.7% Today

StoneCo Ltd. ($STNE) Stock Forecast: Up 11.4% Today

Intuit Inc. ($INTU) Stock Forecast: Down 5.1% Today

Avalanche ($AVAX) Crypto Forecast: Up 11.0% Today

Kohl's Corporation ($KSS) Stock Forecast: Up 5.0% Today

Zoom Video Communications Inc. ($ZM) Stock Forecast: Up 5.4% Today

Prime Medicine Price History

30.08.2024 - PRME Stock was down 9.9%

• PRME stock experienced a bearish movement despite positive news and collaborations with Bristol Myers Squibb, indicating a possible sell-off by investors.
• The market may have reacted negatively to the news of a strategic research collaboration and license agreement with Bristol Myers Squibb, possibly due to concerns about the financial terms of the deal.
• Despite unveiling a strategically focused pipeline and positive developments in cell therapy, investors might have been disappointed with the lack of immediate revenue-generating opportunities, leading to the bearish movement in PRME stock.
• The overall market sentiment and broader industry trends could have also influenced the bearish movement in PRME stock, despite the company's positive announcements.

02.09.2024 - PRME Stock was down 10.8%

• PRME stock rose by 11.8% due to a collaboration announcement with Bristol Myers Squibb for the development of T-cell therapies.
• Despite positive developments, PRME faced a bearish trend, possibly due to profit-taking by investors after a recent sharp rise in stock price.
• The overall market sentiment was slightly lower with the Dow Jones index falling around 0.1%, which might have contributed to the downward pressure on PRME stock.
• Investors might be cautious about the timeline for the initial clinical data from Phase 1/2 trials in CGD expected in 2025, leading to some selling pressure on the stock.

30.08.2024 - PRME Stock was up 5.4%

• PRME stock surged after announcing a partnership with Bristol Myers Squibb worth over $3.5 billion.
• The unveiling of a strategically focused pipeline by Prime Medicine and the efficiency of their Prime Editing Platform likely contributed to investor optimism.
• The collaboration with Bristol Myers Squibb and the promising clinical data expected from their Phase 1/2 trial in 2025 could have further fueled investor enthusiasm for PRME.

26.05.2024 - PRME Stock was down 5.1%

• The bearish movement in PRME stock can be linked to a recent downgrade to a "sell" rating. This action, combined with other analysts' assessments, likely prompted investors to divest their holdings in the company.
• Investors' negative response to a coverage initiation contributed to higher selling activity of PRME shares.
• The change in sentiment from neutral to sell suggests potential concerns about the company's future performance or internal developments creating uncertainty among investors.

29.04.2024 - PRME Stock was down 8.5%

• PRME's bearish movement today could be due to profit-taking by investors following strong gains in the biotech sector.
• Highlighting Moderna as a top biotech stock to buy in May may have diverted investor attention from PRME, resulting in a sell-off.
• The mention of a potential breakout in the biotech sector might have heightened expectations for other stocks, leading to PRME's underperformance.
• Investors could be reallocating their investments to other biotech stocks with more promising prospects, impacting PRME's stock price negatively.

16.04.2024 - PRME Stock was up 5.1%

• PRME received an upgrade to a "Sell" rating, despite the positive movement in the stock.
• The consensus among analysts points to a considerable upside for PRME in terms of price target, reflecting optimism from financial experts.
• PRME exceeded earnings per share expectations for the first quarter of 2024, likely influencing the bullish performance.
• The news of Prime Medicine's participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference may have also enhanced investor confidence in the company's future outlook.

20.04.2024 - PRME Stock was up 5.1%

• PRME stock experienced a strong bullish movement recently.
• The surge in PRME's stock price could be attributed to a recommendation to investors to pick up shares of Prime Medicine as it regains the market's favor.
• Additionally, the consensus price target hinting at a significant upside potential for PRME might have further fueled investor optimism and contributed to the bullish market movement.
• The upgrade to a "sell" rating might have initially caused some uncertainty, but the overall positive outlook from various sources and the potential for significant growth likely overshadowed this downgrade.

14.04.2024 - PRME Stock was up 5.6%

• Prime Medicine exceeded EPS expectations for Q1 2024 with earnings per share of -44 cents, surpassing analyst forecasts. This positive earnings outcome likely influenced the upward movement.
• The company revealed preclinical data demonstrating PM359's ability to correct disease-causing mutations, showcasing promising progress in their pipeline. This development may have increased investor confidence in the company's future.
• Prime Medicine's participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ might have attracted positive attention and interest from potential investors, further fueling the upward trend.
• The consensus price target indicating a significant upside potential for PRME could have drawn in more investors, resulting in increased buying pressure and driving the stock price up.

11.06.2024 - PRME Stock was up 7.8%

• PRME was recently upgraded to a "sell" rating, potentially signaling a change in investor sentiment.
• Conflicting ratings, such as an "outperform" rating alongside the recent "sell" rating, may be contributing to volatility in PRME's stock price.
• The mixed signals from different brokerages are causing uncertainty among investors, leading to increased buying activity and pushing the stock price up.
• The market movement could also be influenced by broader industry trends or upcoming developments in Prime Medicine's pipeline that are not reflected in the current ratings.

19.06.2024 - PRME Stock was down 6.3%

• The bearish movement in PRME today could be attributed to investors taking a cautious stance due to the company's current cash position.
• Despite the positive pipeline progress, the uncertainty surrounding the financial stability of PRME might have led to profit-taking by investors.
• The recommendation to adopt a wait-and-watch approach suggests that market participants are hesitant to make significant moves until there is more clarity on PRME's financial situation.

01.07.2024 - PRME Stock was down 5.0%

• PRME stock registered a bearish movement possibly due to worries about its cash position.
• Investors are exercising caution in anticipation of Prime Medicine's Q2 earnings, resulting in selling pressure.
• The company's financial stability concerns and the approaching earnings report likely influenced the negative market sentiment surrounding PRME today.

09.07.2024 - PRME Stock was down 5.3%

• Prime Medicine (PRME) reported earnings per share of -46 cents for Q2 2024, missing the analyst estimate of -41 cents.
• The company did not report any revenue for the quarter, which likely contributed to the negative market sentiment.
• Investors may have reacted negatively to the earnings miss, leading to the bearish movement in PRME stock.
• The disappointing earnings report could have raised concerns about the company's financial performance and future prospects, prompting investors to sell off their positions in PRME.